Biomarkers in Ewing sarcoma: the promise and challenge of personalized medicine. A report from the Children's Oncology Group

Shukla, Neerav; Schiffman, Joshua; Reed, Damon; Davis, Ian J.; Womer, Richard B.; Lessnick, Stephen L.; Lawlor, Elizabeth R.
June 2013
Frontiers in Oncology;Jun2013, Vol. 3, p1
Academic Journal
A goal of the COG Ewing Sarcoma (ES) Biology Committee is enabling identification of reliable biomarkers that can predict treatment response and outcome through the use of prospectively collected tissues and correlative studies in concert with COG therapeutic studies. In this report, we aim to provide a concise review of the most well-characterized prognostic biomarkers in ES, and to provide recommendations concerning design and implementation of future biomarker studies. Of particular interest and potentially high clinical relevance are studies of cell-cycle proteins, sub-clinical disease, and copy number alterations. We discuss findings of particular interest from recent biomarker studies and examine factors important to the success of identifying and validating clinically relevant biomarkers in ES. A number of promising biomarkers have demonstrated prognostic significance in numerous retrospective studies and now need to be validated prospectively in larger cohorts of equivalently treated patients. The eventual goal of refining the discovery and use of clinically relevant biomarkers is the development of patient specific ES therapeutic modalities.


Related Articles

  • Serum Levels of Vasoactive Intestinal Peptide as a Prognostic Marker in Early Arthritis. Martínez, Carmen; Ortiz, Ana M.; Juarranz, Yasmina; Lamana, Amalia; Seoane, Iria V.; Leceta, Javier; García-Vicuña, Rosario; Gomariz, Rosa P.; González-Álvaro, Isidoro // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    Objective: Suitable biomarkers are essential for the design of therapeutic strategies in personalized medicine. Vasoactive intestinal peptide (VIP) has demonstrated immunomodulatory properties in autoimmune murine and ex vivo human models. Our aim was to study serum levels of VIP during the...

  • DNA Methylation Biomarkers: Cancer and Beyond. Mikeska, Thomas; Craig, Jeffrey M. // Genes;Sep2014, Vol. 5 Issue 3, p821 

    Biomarkers are naturally-occurring characteristics by which a particular pathological process or disease can be identified or monitored. They can reflect past environmental exposures, predict disease onset or course, or determine a patient's response to therapy. Epigenetic changes are such...

  • Personalized Medicine in Pancreatic Cancer: Prognosis and Potential Implications for Therapy. Iacobuzio-Donahue, Christine // Journal of Gastrointestinal Surgery;Sep2012, Vol. 16 Issue 9, p1651 

    No abstract available.

  • Unusual Presentation of a Primary Ewing's Sarcoma of the Spine with Paraplegia: A Case Report. KANNAN, KARTHIK KAILASH; SUNDARAPANDIAN, RAJKUMAR JAYACHANDRAN; SURULIVEL, VIGNESH JAYABALAN // Journal of Clinical & Diagnostic Research;Mar2015, Vol. 9 Issue 3, p1 

    Ewing's sarcoma is a primary malignancy of the bone affecting individuals in the second decade of life. Primary sarcomas of the spine are rare and the occurrence of Primary Ewing's sarcoma in the spine is very rare. Ewing's sarcoma occurring in the spine is divided into two types, Ewing's...

  • A simple and reproducible breast cancer prognostic test. Marchionni, Luigi; Afsari, Bahman; Geman, Donald; Leek, Jeffrey T. // BMC Genomics;2013, Vol. 14 Issue 1, p1 

    Background: A small number of prognostic and predictive tests based on gene expression are currently offered as reference laboratory tests. In contrast to such success stories, a number of flaws and errors have recently been identified in other genomic-based predictors and the success rate for...

  • Personalized Targeted Therapy for Lung Cancer. Wu, Kehua; House, Larry; Liu, Wanqing; Cho, William C. S. // International Journal of Molecular Sciences;Sep2012, Vol. 13 Issue 9, p11471 

    Lung cancer has long been recognized as an extremely heterogeneous disease, since its development is unique in every patient in terms of clinical characterizations, prognosis, response and tolerance to treatment. Personalized medicine refers to the use of markers to predict which patient will...

  • Metabolomics in rheumatology. Kapoor, Sabrina R.; McGrath, Catherine M.; Fitzpatrick, Martin A.; Young, Stephen P. // Rheumatology;Dec2015, Vol. 54 Issue 12, p2124 

    The author discusses metabolomics in rheumatology and how it has the potential to provide a holistic view of patients and their disease. Topics covered include how rheumatoid arthritis (RA) was first associated with altered levels of individual metabolites in a 1962 report which described...

  • Bilateral endoprosthetic replacements of the proximal femur. Foukas, Athanasios F.; Grimer, Robert J. // Sarcoma;Mar1998, Vol. 2 Issue 1, p49 

    Patient . We report the case of a 20-year-old caucasian male with an Ewing's sarcoma in the left upper femur. After induction chemotherapy, he underwent resection of the left upper femur and insertion of a cemented proximal femoral replacement. Four years later, he presented with a solitary bone...

  • Detection of (11;22)(q24;q12) translocation-bearing cells in peripheral blood progenitor cells of... Toretsky, Jeffrey A.; Neckers, Leonard // JNCI: Journal of the National Cancer Institute;3/1/95, Vol. 87 Issue 5, p385 

    Evaluates whether t(11;12)-positive cells would be detected in peripheral blood progenitor cell collections and if they would disappear with treatment of Ewing's sarcoma. Monitoring of patients whose tumors contain a translocation from minimal residual disease; Bone marrow biopsies required...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics